Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir vs Valacyclovir for CMV Prophylaxis in Alemtuzumab Patients
NCT00562770Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: CBC, platelet and differential, BUN, creatinine, total bilirubin, alkaline phosphatase, LDH, SGPT at 20 weeks. Started Sep 2003; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00562770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562770.